Nature Nanotechnology: Tissue-Specific mRNA Therapeutic Delivery
Researchers have developed a combinatorial design of siloxane-incorporated LNPs to enhance tissue-specific mRNA therapeutic delivery. This article explains how this approach improves intracellular processing and stability of mRNA, showing promise for targeted treatments and efficient gene expression in various tissues.
Nobel Prize in Physiology or Medicine
Victor Ambros and Gary Ruvkun have been awarded the 2024 Nobel Prize in Physiology or Medicine for their discovery of microRNA and its role in post-transcriptional gene regulation. This discovery has unveiled a new dimension of gene regulation essential for the development and function of multicellular organisms, with implications for understanding and treating various diseases.
Harnessing mRNA Quality Insights—Essential Techniques for Rapid Drug Development
Register for this upcoming webinar on November 11 to discover how mRNA quality and advanced analytics are key players in the successful development of mRNA-based therapeutics. During, you’ll dive into the critical quality attributes (CQAs) of mRNA and LNPs that directly impact drug efficacy and safety.
mRNA Cancer Vaccine Shows Potential
A Phase I trial of an experimental mRNA cancer vaccine showed promise for patients with advanced solid tumors, including lung and melanoma. Interim results indicate the vaccine can stimulate an immune response and is tolerated, with manageable side effects. Although the study involved a small patient cohort, findings suggest the vaccine’s potential to improve patient outcomes and support further research into personalized cancer treatments.
mRNA Vaccine for Protection Against C.Diff
Researchers have developed a flexible mRNA vaccine that effectively protects mice from deadly Clostridioides difficile (C. diff) infections, including recurrent cases. This promising vaccine could potentially offer a new approach to preventing these challenging and often recurring infections in humans.
Measure Quality Attributes Faster
Efficiently and confidently assess critical quality attributes (CQAs) throughout every phase of drug development—from discovery to clinical trials. Explore mRNA and LNP Analytical Services available to researchers like you.
Self-Amplifying mRNA COVID-19 Vaccine
A new, 12-month study found that a self-amplifying mRNA COVID-19 vaccine (ARCT-154) works better than the traditional Comirnaty® vaccine. This research, conducted in Japan with 828 people, showed ARCT-154 produced more antibodies against different virus strains, which helps the immune system fight off COVID-19, suggesting ARCT-154 could be a more effective option for vaccines.